Marcus Maurer Selected Research

Histamine Antagonists (Antihistamines)

1/2022	Autoimmune chronic spontaneous urticaria.
1/2022	An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
11/2021	Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.
11/2021	Expert consensus on the use of omalizumab in chronic urticaria in China.
10/2021	Predictors of treatment response in chronic spontaneous urticaria.
3/2021	Worsening of chronic spontaneous urticaria after intake of hot pepper.
1/2021	Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
1/2021	Expert consensus on practical aspects in the treatment of chronic urticaria.
10/2020	Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
9/2020	Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcus Maurer Research Topics

Disease

89	Chronic Urticaria 02/2022 - 06/2008
68	Urticaria (Hives) 02/2022 - 01/2007
35	Hereditary Angioedemas 07/2022 - 04/2010
31	Angioedema 10/2021 - 06/2008
20	Hypersensitivity (Allergy) 01/2022 - 08/2003
19	Inflammation (Inflammations) 01/2021 - 12/2004
16	Pruritus (Itching) 01/2021 - 08/2006
15	Cold Urticaria 01/2022 - 03/2009
13	Chronic Inducible Urticaria 01/2022 - 01/2014
12	Asthma (Bronchial Asthma) 01/2021 - 03/2009
11	Atopic Dermatitis (Atopic Eczema) 01/2021 - 01/2010
9	Anaphylaxis (Anaphylactic Shock) 01/2022 - 10/2009
8	Allergic Rhinitis 01/2021 - 04/2010
7	Familial dermographism 01/2022 - 01/2011
7	Infections 01/2021 - 06/2007
6	Contact Dermatitis (Eczema, Contact) 07/2021 - 08/2003
5	COVID-19 12/2021 - 01/2020
5	Skin Diseases (Skin Disease) 07/2021 - 12/2016
4	Prurigo 01/2022 - 03/2013
4	Solar Urticaria 07/2018 - 01/2011
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 01/2015
3	Schnitzler Syndrome 01/2021 - 04/2017
3	Vasculitis (Vasculitides) 01/2020 - 09/2013
3	Neoplasms (Cancer) 01/2020 - 03/2014
3	Necrosis 01/2017 - 01/2012
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 07/2021
2	Eczema 07/2021 - 12/2014
2	Edema (Dropsy) 04/2021 - 09/2010
2	Nasal Polyps (Nasal Polyp) 01/2021 - 01/2020
2	Rhinosinusitis 01/2020 - 07/2014
2	Neurogenic Inflammation 01/2019 - 04/2008
2	Hereditary Angioedema Types I and II 01/2019 - 11/2018
2	Mastocytosis 01/2018 - 12/2012
2	Rare Diseases (Rare Disease) 04/2017 - 12/2012
2	Alopecia (Baldness) 10/2016 - 06/2007

Drug/Important Bio-Agent (IBA)

62	Omalizumab (Xolair)FDA Link 01/2022 - 09/2010
37	Histamine Antagonists (Antihistamines)IBA 01/2022 - 03/2009
25	Immunoglobulin E (IgE)IBA 01/2022 - 07/2009
17	Cholinergic Agents (Cholinergics)IBA 01/2022 - 02/2014
15	CytokinesIBA 12/2021 - 08/2006
12	icatibantIBA 01/2019 - 04/2010
11	BradykininIBA 08/2021 - 04/2010
11	Histamine (Histamine Dihydrochloride)FDA Link 01/2020 - 06/2008
10	AllergensIBA 01/2022 - 08/2003
9	AutoantibodiesIBA 11/2021 - 04/2011
8	Immunoglobulin G (IgG)IBA 01/2022 - 04/2015
8	Biological ProductsIBA 01/2022 - 01/2017
8	anti-IgE antibodiesIBA 12/2019 - 07/2007
7	Monoclonal AntibodiesIBA 07/2022 - 01/2018
7	rupatadineIBA 12/2019 - 01/2010
6	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022 - 09/2015
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2010
6	lanadelumabIBA 01/2022 - 11/2018
6	AntigensIBA 01/2021 - 01/2012
6	desloratadine (Aerius)FDA LinkGeneric 12/2019 - 03/2009
6	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 08/2006
5	NeuropeptidesIBA 01/2022 - 08/2006
5	AntibodiesIBA 07/2021 - 07/2011
5	Plasma KallikreinIBA 06/2021 - 01/2016
5	Substance PIBA 01/2021 - 06/2007
5	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2012
5	Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)IBA 01/2019 - 10/2008
4	Tryptases (Tryptase)IBA 09/2022 - 10/2009
4	ligelizumabIBA 02/2022 - 10/2019
4	Pharmaceutical PreparationsIBA 01/2021 - 08/2012
4	ChemokinesIBA 01/2015 - 08/2007
3	berotralstatIBA 06/2021 - 01/2018
3	Immunoglobulin A (IgA)IBA 01/2021 - 12/2020
3	dupilumabIBA 01/2021 - 01/2019
3	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 07/2020 - 01/2018
3	canakinumab FDA Link 01/2020 - 09/2013
3	fexofenadine (Allegra)FDA LinkGeneric 12/2019 - 05/2013
3	levocetirizine FDA LinkGeneric 12/2019 - 05/2013
3	C-Reactive ProteinIBA 01/2018 - 05/2013
3	Bradykinin B2 ReceptorIBA 09/2015 - 04/2010
3	Interleukin-33IBA 01/2015 - 04/2012
3	Chymases (Chymase)IBA 02/2014 - 08/2007
3	Interleukin-10 (Interleukin 10)IBA 01/2012 - 08/2003
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2007 - 01/2003
2	AndrogensIBA 01/2022 - 02/2011
2	Iodide Peroxidase (Deiodinase)IBA 01/2022 - 04/2011
2	fenebrutinibIBA 01/2022 - 11/2021
2	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2021
2	InflammasomesIBA 07/2021 - 10/2012
2	CryoglobulinsIBA 01/2021 - 01/2021
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021 - 01/2021
2	Peroxidase (Myeloperoxidase)IBA 01/2021 - 01/2019
2	cold agglutininsIBA 01/2021 - 01/2021
2	mepolizumabIBA 07/2020 - 04/2018
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2020 - 12/2013
2	Biomarkers (Surrogate Marker)IBA 12/2019 - 10/2008
2	Histamine H1 Receptors (Histamine H1 Receptor)IBA 12/2019 - 01/2011
2	Codeine (Codeine Phosphate)FDA LinkGeneric 07/2019 - 01/2012
2	Interleukin-1 (Interleukin 1)IBA 01/2019 - 10/2012
2	AutoantigensIBA 01/2018 - 07/2011
2	Rituximab (Mabthera)FDA Link 08/2017 - 01/2017
2	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 03/2017 - 11/2016
2	montelukast (Singulair)FDA Link 02/2017 - 09/2015

Therapy/Procedure

40	Therapeutics 03/2022 - 01/2007
3	Injections 01/2014 - 09/2006